Natera (NASDAQ:NTRA) Insider Solomon Moshkevich Sells 3,000 Shares

Natera, Inc. (NASDAQ:NTRA) insider Solomon Moshkevich sold 3,000 shares of the company’s stock in a transaction on Monday, February 2nd. The stock was sold at an average price of $231.44, for a total transaction of $694,320.00. Following the transaction, the insider directly owned 139,486 shares in the company, valued at approximately $32,282,639.84. This trade represents a 2.11% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Solomon Moshkevich also recently made the following trade(s):

• On Tuesday, February 3rd, Solomon Moshkevich sold 1,639 shares of Natera stock. The shares were sold at an average price of $230.77, for a total transaction of $378,232.03.
• On Wednesday, January 28th, Solomon Moshkevich sold 1,200 shares of Natera stock. The stock was sold at an average price of $237.66, for a total value of $285,192.00.
• On Tuesday, January 27th, Solomon Moshkevich sold 1,013 shares of Natera stock. The stock was sold at an average price of $240.53, for a total value of $243,656.89.
• On Wednesday, January 21st, Solomon Moshkevich sold 293 shares of Natera stock. The stock was sold at an average price of $235.00, for a total value of $68,855.00.
• On Tuesday, January 20th, Solomon Moshkevich sold 23,205 shares of Natera stock. The stock was sold at an average price of $234.74, for a total value of $5,447,141.70.
• On Friday, January 2nd, Solomon Moshkevich sold 2,951 shares of Natera stock. The shares were sold at an average price of $228.95, for a total value of $675,631.45.
• On Friday, December 12th, Solomon Moshkevich sold 4,692 shares of Natera stock. The stock was sold at an average price of $230.76, for a total value of $1,082,725.92.
• On Monday, December 1st, Solomon Moshkevich sold 3,000 shares of Natera stock. The stock was sold at an average price of $238.15, for a total transaction of $714,450.00.

Natera Trading Down 9.7%

Shares of NASDAQ NTRA opened at $205.61 on Thursday. The company’s 50-day moving average price is $234.95 and its 200 day moving average price is $195.74. Natera, Inc. has a 52 week low of $125.38 and a 52 week high of $256.36. The stock has a market cap of $28.44 billion, a price-to-earnings ratio of -89.79 and a beta of 1.64.

Natera (NASDAQ:NTRA) last announced its quarterly earnings results on Friday, November 7th. The medical research company reported ($0.64) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.39) by ($0.25). Natera had a negative net margin of 14.61% and a negative return on equity of 25.07%. The business had revenue of $592.18 million during the quarter, compared to analysts’ expectations of $514.55 million. During the same period last year, the company earned ($0.26) EPS. The firm’s revenue for the quarter was up 34.7% on a year-over-year basis. As a group, research analysts expect that Natera, Inc. will post -1.49 earnings per share for the current year.

Trending Headlines about Natera

Here are the key news stories impacting Natera this week:

• Positive Sentiment: Natera submitted a Premarket Approval (PMA) to the FDA for Signatera CDx to detect minimal residual disease (MRD) in bladder cancer after positive phase‑3 results — a regulatory win that could create a companion diagnostic revenue stream and improve clinical adoption/reimbursement if approved. Read More.
• Neutral Sentiment: Multiple non‑executive insiders also sold shares this week (Solomon Moshkevich and John Fesko each trimmed small single‑digit percentages of their holdings). These appear to be modest, routine dispositions versus strategic exits but add to selling pressure. Read More.
• Negative Sentiment: CEO Steven Chapman sold 85,299 shares on Feb 2 (~40% reduction in his holding) for a proceeds block of roughly $19.7M — a material insider disposition that investors often view negatively. Read More.
• Negative Sentiment: Additional executive sales this week: CEO Chapman sold another 4,725 shares (Feb 3) and CFO Michael Burkes Brophy sold 6,939 shares (Feb 3), each trimming double‑digit or mid‑single digit ownership percentages — reinforcing near‑term downward pressure on the stock. Read More. Read More.

Institutional Trading of Natera

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Flagship Harbor Advisors LLC acquired a new position in Natera during the fourth quarter valued at approximately $41,000. Hilltop National Bank purchased a new position in shares of Natera in the 2nd quarter valued at $33,000. Horizon Investments LLC acquired a new position in shares of Natera during the 3rd quarter valued at $32,000. Sound Income Strategies LLC boosted its position in Natera by 95.7% during the 3rd quarter. Sound Income Strategies LLC now owns 225 shares of the medical research company’s stock worth $39,000 after purchasing an additional 110 shares during the period. Finally, TD Waterhouse Canada Inc. acquired a new stake in Natera in the 4th quarter valued at $62,000. Institutional investors and hedge funds own 99.90% of the company’s stock.

Analyst Ratings Changes

Several brokerages have recently issued reports on NTRA. Evercore ISI upped their price objective on Natera from $190.00 to $250.00 and gave the company an “outperform” rating in a research report on Friday, November 7th. Zacks Research raised shares of Natera from a “strong sell” rating to a “hold” rating in a research note on Thursday, January 1st. TD Cowen restated a “buy” rating on shares of Natera in a report on Wednesday, January 7th. Wells Fargo & Company lifted their price target on shares of Natera from $190.00 to $205.00 and gave the stock an “equal weight” rating in a report on Monday, December 15th. Finally, Barclays boosted their price objective on shares of Natera from $230.00 to $270.00 and gave the company an “overweight” rating in a research report on Monday, December 15th. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Natera presently has an average rating of “Moderate Buy” and an average target price of $249.20.

About Natera

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.